Prosecution Insights
Last updated: April 19, 2026
Application No. 18/977,253

LIQUID-CRYSTAL MEDIUM

Non-Final OA §102
Filed
Dec 11, 2024
Examiner
VISCONTI, GERALDINA
Art Unit
1737
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Merck Patent GmbH
OA Round
2 (Non-Final)
86%
Grant Probability
Favorable
2-3
OA Rounds
2y 5m
To Grant
88%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allow Rate
1146 granted / 1325 resolved
+21.5% vs TC avg
Minimal +2% lift
Without
With
+1.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
36 currently pending
Career history
1361
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
23.9%
-16.1% vs TC avg
§102
23.9%
-16.1% vs TC avg
§112
32.2%
-7.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1325 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is responsive to the Amendment and Remarks filed 28 October 2025. Claims 1-16 remain pending and presently under consideration in this application. Response to Amendment The rejection of claims under 35 U.S.C. 112(b) or 35 U.S.C. 112(pre-AIA ), second paragraph, as set forth in paragraph 4 of the previous office action on the merits, is hereby withdrawn in view of applicant’s amendment to the same. Response to Arguments Applicant's arguments filed 28 October 2025 with respect to the rejection of claims over each of Huang et al. (U.S. Patent No. 12,104,109) and Laut et al. (U.S. Patent Application Publication No. 2024/0067879), as respectively set forth in paragraphs 7 and 8 of the previous office action on the merits, said argument to the effect that the rejections are moot in view of applicants’ statement of common ownership pursuant to 35 U.S.C. 102(b)(2)(C), have been fully considered and are persuasive. The aforementioned rejections have been withdrawn. Applicant’s arguments filed 28 October 2025 with respect to the alleged allowability of the claims have been considered but are moot because the arguments do not apply to any of the references being used in the current rejection. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-16, are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hirschmann et al. (U.S. Patent Application Publication No. 2023/0272282). Hirschmann et al. discloses a liquid crystal medium and the corresponding use thereof said liquid crystal medium in a liquid crystal display, characterized in that said liquid crystal medium preferably comprises at least one compound of the present formula I, i.e., CC-4-V1 ([0478], p. 87) and at least one compound of the present formula CPY, i.e., CPY-2-O2 ([0473], p. 87). The inventive liquid crystal medium of Hirschmann et al. further comprises a combination of compounds inclusive of the compounds of the present claims: at least one compound inclusive of the compounds of the present formulae IIA, IIB, IIC, and IID, as respectively represented therein by PNG media_image1.png 555 423 media_image1.png Greyscale ([0076], p. 5+), at least one compound inclusive of the compound of the present formula III as recited in claim 2, as generally represented therein by PNG media_image2.png 124 387 media_image2.png Greyscale ([0028], p. 3+), at least one compound inclusive of the compound of the present formula VI as recited in claim 3, as generally represented therein by PNG media_image3.png 136 413 media_image3.png Greyscale ([0158], p. 36), at least one compound inclusive of the compound of the present formulae Z-1 thru Z-8 as recited in claim 5, as generally respectively represented therein by PNG media_image4.png 123 373 media_image4.png Greyscale PNG media_image5.png 113 367 media_image5.png Greyscale PNG media_image6.png 124 386 media_image6.png Greyscale PNG media_image7.png 129 403 media_image7.png Greyscale PNG media_image8.png 119 391 media_image8.png Greyscale PNG media_image9.png 119 393 media_image9.png Greyscale PNG media_image10.png 120 517 media_image10.png Greyscale and PNG media_image11.png 129 418 media_image11.png Greyscale ([0171], p. 40], at least one compound inclusive of the compound of the present formula IV as recited in claim 6, as generally represented therein by PNG media_image12.png 86 392 media_image12.png Greyscale ([0118], p. 28), and at least one compound inclusive of the compound of the present formula IVb-1 to IVb-3 as recited in claim 7, as respectively represented therein by PNG media_image13.png 237 390 media_image13.png Greyscale ([0143], p. 31), at least one compound inclusive of the compound of the present formula V/V-1/V-2/V-3 as recited in claims 8 and 9, as generally represented therein by PNG media_image14.png 109 406 media_image14.png Greyscale ([0149], p. 32), at least one compound inclusive of the compound of the present formula CL as recited in claim 10, as generally represented therein by PNG media_image15.png 295 417 media_image15.png Greyscale ([0196], p. 47), at least one compound inclusive of the compound of the present formula S as recited in claim 12, as generally represented therein by PNG media_image16.png 118 306 media_image16.png Greyscale ([0198], p. 48), and at least one polymerizable compound as recited in claim 13, as generally represented therein by the compounds of formulae R1 through R32 therein ([0374], p. 80+). In fact, the following examples therein expressly illustrates the combination of at least one compound of the present formula I, i.e., CC-4-V1, and at least one compound of the present formula CPY, i.e., CPY-2-O2, with at least one of the aforementioned additional compounds: M28 (p. 133), M43 & M44 (p. 135), M45-M47 (p. 136), M62 (p. 138), M72 (p. 141), M82 (p. 142), M85-M86 (p. 142), M88 (p. 190), and M90 (p. 190). Prior Art The following prior art made of record and not relied upon is considered pertinent to applicant’s disclosure: U.S. Patent Application Publication No. 2025/0215322, which is the pre-grant publication corresponding to the present application. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Geraldina Visconti whose telephone number is (571)272-1334. The examiner can normally be reached Monday-Friday, 8:00am-4:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark F Huff can be reached at 571-272-1385. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. GERALDINA VISCONTI Primary Examiner Art Unit 1737 /GERALDINA VISCONTI/Primary Examiner, Art Unit 1737
Read full office action

Prosecution Timeline

Dec 11, 2024
Application Filed
Jun 03, 2025
Non-Final Rejection — §102
Oct 28, 2025
Response Filed
Feb 17, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595416
LC MIXTURES WITH NEGATIVE DELTA EPSILONCONTAINING CC-4-V1 AND COB(S)-N-OM
2y 5m to grant Granted Apr 07, 2026
Patent 12570900
POLYMERISABLE COMPOUND, POLYMERISABLE LC MATERIAL AND POLYMER FILM
2y 5m to grant Granted Mar 10, 2026
Patent 12565617
POLYMERISABLE OLIGOMERIC LIQUID CRYSTAL, POLYMERISABLE MEDIUM AND POLYMERISED LIQUID CRYSTAL FILM
2y 5m to grant Granted Mar 03, 2026
Patent 12559679
OPTICALLY ANISOTROPIC LAYER, OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE
2y 5m to grant Granted Feb 24, 2026
Patent 12559678
Liquid-crystal medium
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
86%
Grant Probability
88%
With Interview (+1.5%)
2y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 1325 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month